Meng Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Meng Sun has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Wei Zhang
Department of Biostatistics, School of Public Health, Fudan University, Shanghai, China
2 shared publications - Xuan Chen
Department of Respiratory Medicine, Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China
2 shared publications - Cuiping Fu
Department of Respiratory and Critical Care Medicine, First Affiliated Hospital of Soochow University, Suzhou, China
1 shared publication Guihua Xu
Department of Pulmonary Diseases, ShuGuang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China
1 shared publication- Jiacheng Lin
Central Laboratory, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China
1 shared publication Jiamin Wu
Department of Pulmonary Diseases, ShuGuang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China
1 shared publication
Latest Publications
- Open Access
- 4 April 2025
- Published by Wolters Kluwer Health in Rehabilitation Nursing Journal
- Vol. 50 (2) , 78-87
Combined Effect of 12 Weeks Baduanjin and Tri-Ball Respiratory Training as a Home-Based Pulmonary Rehabilitation in Subjects With Moderate Chronic Obstructive Pulmonary Disease: A Multi-Center Randomized Controlled Trial
Background: Despite promising individual benefits, the combined efficacy of Baduanjin and Tri-Ball Breath training as a home-based pulmonary rehabilitation in Chronic Obstructive Pulmonary Disease (COPD) subjects remains unexplored. Objective: The aim of the study was to evaluate the effect of combining Baduanjin (a traditional Chinese exercise) and Tri-Ball Breath training into a home-based pulmonary rehabilitation regimen for COPD patients. Methods: A multicenter randomized controlled trial was conducted, enrolling 240 moderate COPD patients from 10 hospitals. Participants were randomly assigned to four groups: Baduanjin group, Tri-Ball Breath training group, Combination training group, and control group. The intervention lasted 12 weeks. Data were collected at baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks post-intervention. Results: After 12 weeks, the 6-Minute Walk Distance (6MWD) significantly improved in the Baduanjin group and the Tri-Ball Breath training group (p p p p p <0 .05). The vital signs of all participants were stable from the baseline, and no statistic difference was observed among the four groups at all visits. Conclusion: Our findings underscore the significance of incorporating Baduanjin and respiratory muscle training into the long-term management of COPD patients. By fostering continuous improvements in pulmonary function (FEV1%) and exercise capacity (6MWD), these interventions may help to mitigate disease progression and enhance patients' quality of life.
- 4 April 2025
- Published by Wolters Kluwer Health in Rehabilitation Nursing Journal
- Vol. 50 (2) , 78-87
Open AccessCombined Effect of 12 Weeks Baduanjin and Tri-Ball Respiratory Training as a Home-Based Pulmonary Rehabilitation in Subjects With Moderate Chronic Obstructive Pulmonary Disease: A Multi-Center Randomized Controlled Trial
Background: Despite promising individual benefits, the combined efficacy of Baduanjin and Tri-Ball Breath training as a home-based pulmonary rehabilitation in Chronic Obstructive Pulmonary Disease (COPD) subjects remains unexplored. Objective: The aim of the study was to evaluate the effect of combining Baduanjin (a traditional Chinese exercise) and Tri-Ball Breath training into a home-based pulmonary rehabilitation regimen for COPD patients. Methods: A multicenter randomized controlled trial was conducted, enrolling 240 moderate COPD patients from 10 hospitals. Participants were randomly assigned to four groups: Baduanjin group, Tri-Ball Breath training group, Combination training group, and control group. The intervention lasted 12 weeks. Data were collected at baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks post-intervention. Results: After 12 weeks, the 6-Minute Walk Distance (6MWD) significantly improved in the Baduanjin group and the Tri-Ball Breath training group (p p p p p <0 .05). The vital signs of all participants were stable from the baseline, and no statistic difference was observed among the four groups at all visits. Conclusion: Our findings underscore the significance of incorporating Baduanjin and respiratory muscle training into the long-term management of COPD patients. By fostering continuous improvements in pulmonary function (FEV1%) and exercise capacity (6MWD), these interventions may help to mitigate disease progression and enhance patients' quality of life.
- Open Access
- 14 December 2022
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 16, 4251-4267
Efficiency and Safety of Baofei Granules in Chronic Obstructive Pulmonary Disease (Lung and Spleen Qi Deficiency Syndrome): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial
Background: Baofei Granules (BFGs) have been extensively applied in the clinical treatment of chronic obstructive pulmonary disease (COPD) and significantly have affected COPD patients with lung and spleen qi deficiency syndrome. However, the data from previous small-sample clinical trials are limited. This trial aimed to estimate the efficiency and safety of BFGs in COPD with lung and spleen qi deficiency syndrome. Methods: It is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial. The 216 stable COPD patients will be divided randomly in a ratio of 1:1. The whole trial period consists of a 4-week introductory period, a 52-week treatment period and a 48-week follow-up. Study visits occur every 4 weeks during the treatment period and every 12 weeks during the follow-up. All the subjects will receive 10g BFGs or placebo three times per day for 56 weeks and be followed up for 48 weeks. The primary efficiency evaluation outcome will be the frequency and duration of AECOPD, and the secondary efficiency evaluation outcome will be pulmonary function tests (PFTs), modified Medical Research Council (mMRC) dyspnoea scale, six-minute walking test (6MWT), COPD assessment test (CAT) score, traditional Chinese medicine (TCM) syndrome score, the frequency of emergency medication, BODE index, and the time to first Clinically important deterioration (CID). The safety evaluation outcomes will be adverse events (AEs), vital signs, physical examination, twelve-lead electrocardiogram (ECG), and laboratory examinations. All the data will be analyzed by SAS9.4. Discussion: This is the first and largest clinical trial that evaluates the efficiency and safety of BFGs for COPD with lung and spleen qi deficiency syndrome. It will provide valuable clinical evidence for recommendations on COPD management by the integrated TCM and western medicine. Trial Registration: CTR20211280. Date: June 09, 2021. http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=383a370ecd9f43d7af6f1c8585779e1a.
- 14 December 2022
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 16, 4251-4267
Open AccessEfficiency and Safety of Baofei Granules in Chronic Obstructive Pulmonary Disease (Lung and Spleen Qi Deficiency Syndrome): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial
Background: Baofei Granules (BFGs) have been extensively applied in the clinical treatment of chronic obstructive pulmonary disease (COPD) and significantly have affected COPD patients with lung and spleen qi deficiency syndrome. However, the data from previous small-sample clinical trials are limited. This trial aimed to estimate the efficiency and safety of BFGs in COPD with lung and spleen qi deficiency syndrome. Methods: It is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial. The 216 stable COPD patients will be divided randomly in a ratio of 1:1. The whole trial period consists of a 4-week introductory period, a 52-week treatment period and a 48-week follow-up. Study visits occur every 4 weeks during the treatment period and every 12 weeks during the follow-up. All the subjects will receive 10g BFGs or placebo three times per day for 56 weeks and be followed up for 48 weeks. The primary efficiency evaluation outcome will be the frequency and duration of AECOPD, and the secondary efficiency evaluation outcome will be pulmonary function tests (PFTs), modified Medical Research Council (mMRC) dyspnoea scale, six-minute walking test (6MWT), COPD assessment test (CAT) score, traditional Chinese medicine (TCM) syndrome score, the frequency of emergency medication, BODE index, and the time to first Clinically important deterioration (CID). The safety evaluation outcomes will be adverse events (AEs), vital signs, physical examination, twelve-lead electrocardiogram (ECG), and laboratory examinations. All the data will be analyzed by SAS9.4. Discussion: This is the first and largest clinical trial that evaluates the efficiency and safety of BFGs for COPD with lung and spleen qi deficiency syndrome. It will provide valuable clinical evidence for recommendations on COPD management by the integrated TCM and western medicine. Trial Registration: CTR20211280. Date: June 09, 2021. http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=383a370ecd9f43d7af6f1c8585779e1a.